Lepirudin

Drug Profile

Lepirudin

Alternative Names: HBW 023; HEW 023; Refludan

Latest Information Update: 29 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Class Antithrombotics; Hirudins; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heparin-induced thrombocytopenia and thrombosis syndrome

Highest Development Phases

  • Marketed Heparin-induced thrombocytopenia and thrombosis syndrome
  • Discontinued Deep vein thrombosis; Disseminated intravascular coagulation; Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 08 Mar 2008 Pharmion Corporation has been acquired and merged into Celgene Corporation
  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare (MR 9074204)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top